INTRODUCTION {#sec1-1}
============

Controlled release dosage form is a term used to describe the dosage forms having drug release features based on the time, course and/or location and which are designed to accomplish therapeutic or convenience objectives which are not offered by conventional release dosage forms. However, controlled release dosage form does not provide a rapid onset of action of drug entity. Whereas immediate release drug delivery system is intended to disintegrate rapidly and exhibits instant drug release. However, it is also associated with fluctuations in drug plasma levels, which leads to reduction or loss in drug effectiveness or increased incidence of side-effects. Therefore, to compensate the dip in drug plasma concentration due to metabolism and excretion, it is necessary to administrate the dosage form several times per day. A relatively constant plasma level of a drug is often preferred to maintain the drug concentration within the therapeutic window. However, it is difficult to achieve, especially for once-daily dosage forms. Bilayered tablet is suitable for combination therapy, i.e., for sequential release of two different drugs, separate two incompatible substances and also for sustained release dosage form in which one layer is immediately released as a loading dose and second layer act as a maintenance dose.\[[@ref1][@ref2]\]

On the basis of these considerations, the bilayered tablet have been specially developed to provide two different release rates or biphasic release of a drug from a single dosage form in which one layer is formulated to obtain immediate release effect of the drug, with the aim of reaching a high plasma concentration in a short period of time while the second layer is designed as sustained released layer, which provides effective plasma concentration by a maintenance dose of drug for an extended period of time. The design of bilayered tablet dosage form holds many advantages over conventional dosage forms such as a reduction in frequency of drug administration, improved patient compliance, reduction in drug level fluctuation in blood and quantitative reduction in total drug usage when compared with conventional therapy.\[[@ref3][@ref4][@ref5][@ref6]\]

Hydrochlorothiazide (HCTZ) is a first line diuretic drug from the thiazide class and chemically it is 6-chloro-3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-7-sulphonamide 1, 1-dioxide. It is a drug used in the management of hypertension. HCTZ belongs to biopharmaceutics classification system Class IV, thus this poorly soluble and poorly permeable compound leads to high intra- and inter-subject variability and lack of dose proportionality resulting in fluctuation of dosing with conventional dosage form. HCTZ has been reported to produce significant additive effects in mild to moderate hypertension with twice-daily dosing. Thus, there is a need for the development of bilayered tablet to deliver loading dose of the drug so as to achieve desired onset of action, to reduce the frequency of administration and to increase the efficacy of the drug by providing bimodal drug release pattern.\[[@ref7][@ref8][@ref9]\]

The application of quality-by-design (QbD) approach for formulation development has provided an opportunity for a harmonized pharmaceutical quality system based on continuous quality improvement which can yield safer, more efficacious and quality product.\[[@ref10]\] QbD implementation requires a thorough understanding of the relationship between the critical quality attributes (CQAs) and the clinical properties of the product, leading to successful product development with predefined quality attributes. The fundamental assumption underlying QbD is that if critical sources of variability can be understood then product performance can be controlled using the manufacturing process to mitigate variability in the material properties. Risk management is a "systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle". It is performed to identify material attributes and process parameters whose variability may influence these potential CQAs. The degree of risk can then be used to prioritize the activities for the process characterization.\[[@ref11][@ref12]\] From risk assessment study, high risk parameters will be considered for design of experimentation (DOE) using a suitable model from statistical software tools. By performing the experiments and analyzing data in the selected model; design space is obtained within which product quality can be assured as per the set acceptance criteria.

The present study aims at formulating bilayered tablets of HCTZ which comprises of immediate release layer with croscarmellose sodium; as superdisintegrants, formulated by direct compression techniques while the sustained release layer formulated using several viscosity grades of hydrophilic polymers, which is designed using wet-granulation techniques.

MATERIALS AND METHODS {#sec1-2}
=====================

Materials {#sec2-1}
---------

HCTZ, croscarmellose sodium, HPMC K4M, HPMC K100M, microcrystalline cellulose (MCC) (pH 101 and pH 102), polyvinyl pyrrolidone (PVP) K30, sprays dried lactose and tartrazine were received as gift samples from Medley Pharmaceuticals (Mumbai, India). All other chemicals were of analytical grades.

Preparation of immediate released layer {#sec2-2}
---------------------------------------

HCTZ immediate release tablets were prepared using direct compression method.\[[@ref13][@ref14][@ref15]\] The active ingredient, MCC, lactose and croscarmellose sodium were mixed geometrically. Magnesium stearate and talc were further added as a lubricant to the above dry mix and were mixed well. The colorant tartrazine was then mixed homogenously to get uniform blend without mottling. The whole blend was passed though mesh \#40 and was subjected to compression using 8.00 mm flat faced punch on single stroke punching machine to form immediate released tablet.

Preparation of sustained released layer {#sec2-3}
---------------------------------------

HCTZ sustained release layer were prepared by wet granulation method.\[[@ref16][@ref17][@ref18]\] The active ingredient, HPMC K4M, HPMC K100M, MCC PH 102 and spray-dried lactose were passed through mesh \#40 and were mixed homogenously. PVP K30 (5%) was added as a binder to the above blend and was mixed to get a final coherent mass. Obtained coherent mass was passed through mesh \#20 to get desired granules. The granules were primarily air dried and were finally dried at 50°C until a constant Loss on Drying (LOD) reaches 3-4% analyzed by moisture analyzer. The whole blend of dried granules was lubricated and homogenously mixed by magnesium stearate and talc.

Tablet compression {#sec2-4}
------------------

The bilayered tablet compression was made using 8.00 mm flat punch on a 12-station rotary tablet machine. In that, sustained release HCTZ granules were introduced first into the die cavity and a light pre-compression was imparted so that the layer gets uniformly distributed in the die cavity doesn't mix up with the other layer. Further, immediate release layer blend was added above the previously light pre-compressed sustained release layer and final compression was carried out with optimum compression force.\[[@ref4][@ref14][@ref15]\]

Calculation of dose for bilayered tablet {#sec2-5}
----------------------------------------

The immediate release part of bilayered tablet was calculated using the following equation;\[[@ref19][@ref20][@ref21]\]

D~IR~ = C~p~ × V~d~/F

Where Cp is target serum level, V~d~ is volume of distribution and F is bioavailability factor.

The total dose of HCTZ to deliver a once daily-sustained released formulation was calculated by the following equation using available pharmacokinetic data:

D~SR~ = D~IR~ (1 + 0.693 × t/t~1/2~)

where D~SR~ is a total dose of drug for sustained released layer, D~IR~ is dose of the immediate release part; t is the time (hours) duration for which the sustained release of the drug is desired and t~1/2~ is half-life of the drug.

Risk assessment of critical attributes {#sec2-6}
--------------------------------------

Risk assessment was carried out\[[@ref22]\] and it was observed that both types as well as concentration of polymer and superdisintegrants were critical parameters for the formulation of HCTZ bilayered tablet as shown in \[[Table 1](#T1){ref-type="table"}\].

###### 

Risk assessment parameters to identify variables affecting product quality

![](IJPI-4-93-g001)

Experimental design {#sec2-7}
-------------------

With thorough risk assessment of critical material and process attributes and from the results of preliminary batches of bilayered tablets, 2^2^ full factorial design in replicate was selected with 8 experiments to carry out for applying DOE as shown in \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].\[[@ref22][@ref23]\] The independent variables for this study were concentration of superdisintegrants (X~1~) and drug:polymers blend (X~2~) whereas the dependent variables were disintegration time (DT) (Y~1~) and T~100%~ (Y~2~) of bilayered tablet.

###### 

Experimental design of HCTZ bilayered tablet as per 2^2^ factorial designs

![](IJPI-4-93-g002)

###### 

Formulation design of HCTZ bilayered tablet as per design 2^2^ layout

![](IJPI-4-93-g003)

Evaluation {#sec2-8}
----------

### Evaluation of granules flow properties {#sec3-1}

The prepared granules were evaluated for parameters such as bulk density, tap density, compressibility index, Hausner\'s ratio and angle of repose as per the pharmacopoeial specification.

### Evaluation of tablet {#sec3-2}

Tablets were evaluated for hardness, weight variation, friability and drug content as per pharmacopoeial methods. A total of 20 tablets were triturated and an accurately weighed powder equivalent to 50 mg of HCTZ was dissolved in 10 ml of methanol in a volumetric flask, 70 ml of 6.8 pH phosphate buffer was added into the same volumetric flask and was allowed to sonicate for 10 min and the solution was filtered through 0.45 μm membrane filter (Millipore millex-HN, Nylon 0.45 μm), then the final volume was adjusted with 6.8 phosphate-buffered saline, i.e., up to 100 ml. The absorbance was measured in triplicate using ultraviolet (UV)-visible spectrophotometer at 272 nm after suitable dilution. All results were represented as a mean ± standard deviation (SD).

### In vitro dissolution study {#sec3-3}

*In vitro* dissolution studies were carried out using USP dissolution test apparatus I (basket) at 100 rpm, 37 ± 0.5°C.\[[@ref24][@ref25]\] The dissolution medium was simulated gastric fluid (900 ml) adjusted to pH 1.2 with HCl for initial 2 h and later it replaced with pH 6.8 phosphate buffer (900 ml) and dissolution continued for another 10 h. At different time intervals, samples were withdrawn and filtered using 0.45 μm membrane filter (Millipore millex-HN, Nylon 0.45 μm) and was further analyzed by UV spectrophotometer at 272 nm. The release studies were conducted in triplicate for each batch and the mean values versus time with SD was plotted.

### Characterization of the drug release profile {#sec3-4}

The rate and mechanism of release of HCTZ from prepared bilayered tablets were analyzed by fitting the dissolution data into following exponential equations.\[[@ref9][@ref26]\]

Zero order release equation:

Q = K~0~t

Where Q is the amount of drug released at time t and K~0~ is the zero order release rate constant.

The first order equation:

ln (100 -- Q) = ln 100 -- K~1~ t

Where, K~1~ is the first order release rate constant.

The dissolution data was fitted to the Higuchi\'s equation:

Q = K~2~ t~1/2~

Where, K~2~ is the diffusion rate constant.

The dissolution data was also fitted to the Korsmeyer-Peppas equation, which is often used to describe the drug release behavior from polymeric systems:

Log (Mt/M~∞~) = log K + *n* log t

Where Mt is the amount of drug released at time t, M~∞~ is the amount of drug release after infinite time, K is a release rate constant and *n* is the diffusion exponent indicative of the mechanism of drug release.

For matrix tablets, if the exponent *n* \< 0.5, then the drug release mechanism is quasi-fickian diffusion (If *n* = 0.5 then fickian diffusion and if the value is 0.5 \< *n* \< 1, then it is anomalous diffusion coupled with erosion. An exponent value of 1 is indicative of Case-II Transport or typical zero-order and *n* \> 1 non-fickian super Case II). The diffusion exponent was based on Korsmeyer-Peppas equation.\[[@ref9][@ref26][@ref27]\]

RESULT AND DISCUSSION {#sec1-3}
=====================

Evaluation of granules {#sec2-9}
----------------------

The granules for different formulations of bilayered tablet were evaluated for their physical properties. The bulk and tapped density for prepared granules ranged between 0.40-0.48 g/cm^3^ and 0.44-0.54 g/cm^3^ respectively as determined by the tap method, indicates good packing characteristics. The Carr\'s index and Hausner\'s ratio were ranged from 5.11-12.16% to 1.07-1.14% respectively indicating good flow property.\[[@ref28]\] The flow properties of granules were further analyzed by determining the angle of repose and it ranged between 28.47° and 34.16° respectively. The value indicates a good flow property of granules with HPMC K4M and K100M.\[[@ref28]\]

Physical properties of bilayered tablet {#sec2-10}
---------------------------------------

All the batches of bilayered tablets were produced under similar conditions to avoid processing variables. The drug content, weight variation, hardness, thickness and friability of all formulations were found within acceptable limits as per official specifications shown in \[[Table 4](#T4){ref-type="table"}\]. All batches passes standard weight variation (90-110%) and drug content uniformity (90-110%)\[[@ref29]\] and the observed percentage friability of all batches were less than 1.0%. Values of the hardness test and percent friability indicates that the prepared bilayered tablet have good handling properties.\[[@ref28][@ref29][@ref30]\]

###### 

Post compression parameters of bilayered tablet

![](IJPI-4-93-g004)

DT {#sec2-11}
--

DT for all formulation was observed to be less than 2 min, whereas it decreased with an increase in the concentration of superdisintegrant.

*In vitro* dissolution study {#sec2-12}
----------------------------

The release profile of HCTZ bilayered tablets were analyzed by plotting the cumulative percentage drug release versus time as shown in \[[Figure 1](#F1){ref-type="fig"}\]. *In vitro* study revealed initial burst release up to 30% from the immediate release layer of bilayered tablet; further study was carried out for 12 h to determine release profile of sustained release layer. Drug release from sustained release layer was mainly dependent on polymer concentration. T~100~ % was obtained in 9 h for formulation containing low level of polymer blend. Drug release was retarded up to 12 h with an increase in concentration of polymer blend of HPMC K4M and HPMC K 100M.

![*In vitro* drug dissolution profile of bilayered tablet in 0.1N HCL and 6.8 pH phosphate-buffered saline medium](IJPI-4-93-g005){#F1}

Drug release kinetics {#sec2-13}
---------------------

The kinetics of drug release from bilayered sustained released tablets was determined based on equation obtained by *in vitro* dissolution data to various kinetics models and by the value of 'n' i.e., release exponent. The *n* value is used to interpret the release mechanism. The kinetic data obtained for all formulations of bilayered tablets are shown in \[[Table 5](#T5){ref-type="table"}\]. According to the results of different kinetic models, the *R*^2^ value of Korsmeyer-Peppas model was close to 1 and *n* value was found to be within 0.8530-0.9638. Hence, the release kinetics best fits to Korsmeyer-Peppas model and the mechanism of drug release was regarded as anomalous diffusion of drug from matrix.\[[@ref9][@ref27]\]

###### 

Model fitting data of HCTZ sustained released tablet for drug release kinetics

![](IJPI-4-93-g006)

Statistical design and analysis {#sec2-14}
-------------------------------

The 2^2^ design in replicate mode with '8-runs' was used in the present study to evaluate the main effects of two independent variables selected as high risk parameters, which affects product quality from the risk assessment analysis study. The 2^2^ design application considerably reduces the number of experiments that are required to evaluate the main effects.\[[@ref23][@ref31]\]

Effect on DT {#sec2-15}
------------

Polynomial equation 1 depicts significant effects of X~1~ and X~2~ on DT. The negative value for the coefficient, X~1~ in the equation 1 indicates decrease in the DT for immediate release layer of bilayered tablet with an increase in the concentration superdisintegrants. While the positive value of the coefficient of X~2~ indicates an increase in the response of Y~1~. The relationships between variables were further elicited using half-normal plots/pareto charts as shown in \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\]. In half-normal plot, large effects (absolute values) appear in the upper-right section of the plot, i.e., concentrations of superdisintegrants have more significant effect on DT as compared to polymer blend. In pareto chart, effects above the Bonferroni limit are almost certainly significant, i.e., X~1~, while effects above the T-value limit are possibly significant, i.e., X~2~. The two levels of independent variables indicate the linearity in surface response shown in \[[Figure 4](#F4){ref-type="fig"}\]. This indicates, as the concentration of superdisintegrants increases the DT for immediate released layer decreases, the similar results were reported by Karwa and Kasture\[[@ref19]\] This is because the increase in the concentration of superdisintegrants absorbs the more dissolution medium and disintegrates rapidly.

![Half-normal plot of the formulation variables affecting on disintegration time](IJPI-4-93-g007){#F2}

![Pareto chart for the formulation variables affecting on disintegration time with Bonferroni limit](IJPI-4-93-g008){#F3}

![Surface response plot (3D) demonstrating influence of concentration of superdisintegrants and drug:total polymer ratio on the T100%](IJPI-4-93-g009){#F4}

Y~1~ = 68.63 − 7.63 X~1~ + 2.62 X~2~ + 0.38 X~1~ X~2~ (1)

The calculated *F* value, *P* value and Student t value for response Y~1~ and Y~2~ as shown in \[Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}\] respectively for main response and individual terms of equation, indicates a significant effect of the two factors on the response Y~1~ (DT) and Y~2~ (DR T~100~ %).

###### 

Analysis of variance for DT

![](IJPI-4-93-g010)

###### 

Analysis of variance for time required for total drug release (T100%)

![](IJPI-4-93-g011)

Effect on T~100~ % (time required for total drug release) {#sec2-16}
---------------------------------------------------------

Polynomial equation 2 reveals significant effects of independent variables on response T~100~ %. In the case of response Y~2~, the X~1~ coefficient was negative while the X~2~ was positive according to equation 2. Theoretically it means that, as the concentration of superdisintegrants increases the dissolution time decreases. While the drug:polymers blend (X~2~) increases to high level (+1), T~100~ % increases up to 12 h as compared to low level of (−1), which was also observed in earlier preliminary batches of sustained released formulation and also reported by Atram\[[@ref30]\] In half-normal plots for DR T~100~ %, it was confirmed that drug:polymers blend has a large effect as compared to concentration of superdisintegrants as shown in \[[Figure 5](#F5){ref-type="fig"}\].

![Half-normal plot of the formulation variables affecting on T100%](IJPI-4-93-g012){#F5}

Y~2~ = 645 − 15.0 X~1~ + 75.0 X~2~ (2)

In pareto chart \[[Figure 6](#F6){ref-type="fig"}\], effect above the Bonferroni limit, i.e., drug:polymer blend is certainly significant, while the effect below the T-value limit, concentration of superdisintegrants is possibly significant. The effect of two independent variables was found to be linear in surface response of DR T~100~ % \[[Figure 7](#F7){ref-type="fig"}\]. Decrease in drug release was due to the matrix and integrity of matrix of hydrophilic polymer. The increased viscosity of layer controls the penetration of medium through gel layer and hence the drug diffusion and dissolution was controlled. As the concentration of hydrophilic polymer increases the strength and viscosity of the gel layer formed by polymer also increases and hence the matrix of tablet maintains their integrity for a long period of time depending on concentration of polymer and the ultimately drug release was sustained.

![Pareto chart for the formulation variables affecting on T100% with Bonferroni limit](IJPI-4-93-g013){#F6}

![Surface response plot (3D) demonstrating influence of concentration of superdisintegrants and drug:total polymer ratio on the T100%](IJPI-4-93-g014){#F7}

Establishing design space and control strategy {#sec2-17}
----------------------------------------------

The design space within the QbD-approach represents the whole range of interactions between critical material and process parameters and their effects on CQAs that has been examined during process characterization studies to provide assurance on drug product quality.\[[@ref22][@ref23]\]

During the process and formulation variable characterization study, the impact of the input parameters such as concentration of superdisintegrants and drug-to-total polymer ratio on DT of immediate released layer and time for total drug release (T~100%~) for sustained released layer were assessed. The criteria considered for responses of DT and T~100%~ for design space was less than 180 s and 720 min respectively. This study provide the knowledge space and ultimately design space from multidimensional combination of concentration of superdisintegrants and drug-to-total polymer ratio and thus gives the acceptable operating ranges. The variables ranked as high risk in the initial risk assessment and needed to be controlled in their acceptable ranges were included in the control strategy. The design space shown in \[[Figure 8](#F8){ref-type="fig"}\], it also called as overlay plot. The shaded region with dark yellow color indicates the region of successful operating ranges.

![Design space (overlay plot) for bilayered tablet for validation of optimized formulations](IJPI-4-93-g015){#F8}

Validation of optimized formulations {#sec2-18}
------------------------------------

From the polynomial equations generated for each responses using Design Expert software (8.0.4) (by Stat-Ease Inc.), intensive grid and integrated search was performed over the experimental domain and three optimized formulations were selected (B1-B3). The composition of the checkpoints, the predicted and experimental values of all the response variables (DT and T1~00%~) and the percentage error in prognosis were as shown in \[[Table 8](#T8){ref-type="table"}\]. According to the statistical equivalence percentage standard error for experimental data and predicted values, it was demonstrating the validity of the applied model.

###### 

Comparison of experimental results with predicted responses of optimized formulations

![](IJPI-4-93-g016)

CONCLUSION {#sec1-4}
==========

This work has demonstrated the successful implementation of QbD approach, 2^2^ factorial design, polynomial equations and surface response plot in optimizing formulation variables of HCTZ bilayered tablets. Risk assessment was carried out for various process and formulation variables for their effect on DT of immediate released layer and time required for total drug release (T~100%~) from the matrix of sustained release layer of bilayered tablets. High risk variables were selected for applying DOE. 2^2^ factorial design was used, with concentration of superdisintegrants (X~1~) and drug:total polymer ratio (X~2~) as independent variables and DT (Y~1~) and time required for drug release from matrix (Y~2~) as responses. The bilayered tablets shows an initial burst release to achieve loading dose of the drug, followed by sustained release for 12 h, indicating a promising potential of the HCTZ bilayered tablet as an alternative to the conventional dosage form. The predicted and experimental values of all the response variables form validation batch according to design were correlated and the percentage error in prognosis was determined. These correlation plots demonstrated higher values of *R*^2^, indicating excellent fitting of model. Here, implementing and using statistical tools renders robust formulation and also help in optimizing variables, this leads to structuring a sensitive yet well-controlled, formulation to deliver drug for biphasic drug delivery. It can be concluded that QbD principles and tools play an important role in facilitating a higher-level of process understanding and create opportunities for root-of-cause investigation and developing control strategies in the formulation and process development.
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